Metamizole sodium continues to be used extensively as an analgesic in Poland. This study was the first undertaken to quantify the incidence of agranulocytosis associated with metamizole sodium in Poland, and to compare the findings with those from other countries. Based on data obtained retrospectively from medical records covering the period 1997 -2001 in six haematology centres representative of Poland as a whole, the crude estimate obtained was a rate of 0.2 cases per million person-days of use. This is the same order of magnitude as the value from an epidemiological study covering several countries (0.3 -4.0).
Introduction
Agranulocytosis is a rare, unpredictable, but severe, idiosyncratic reaction. Historically, approximately 10% of cases were fatal. 1 With the availability of modern treatments, however, this rate has declined significantly. It has been suggested that 65 -68% of the occurrences of agranulocytosis can be attributed to drugs, 2,3 and more than 100 different agents have been implicated. 4, 5 Agranulocytosis associated with metamizole sodium is thought to be an immune-mediated reaction. The clinical features can appear after a few days and normally no later than 1 -3 months after initiation of drug administration. 6 They include fever, chills, arthralgia and severe prostration, and there may also be evidence of infection. 7 The efficacy of metamizole sodium as an analgesic has been demonstrated in several double-blind, comparative clinical trials. 8 Concerns about its safety have persisted since it was taken off the market in several countries in the 1970s after reports of fatal agranulocytosis among users. 9 At that time, the risk associated with its use had not been quantified, and the only available data were from single cases and spontaneous reports where causality had not been ascertained using any formal or rigorous approach. These disciplines were only developed in the late 1970s. 10 However, there is no evidence in the literature of their application to drug-induced cases of agranulocytosis prior to 1986. 4 In addition, many of the reported cases lacked complete information to judge, with any degree of certainty, the causality between the drug and the adverse event. 4 Robust quantification of the incidence of metamizole sodium-induced agranulocytosis became available in 1986 with the publication of the International Agranulocytosis and Aplastic Anemia Study (IAAAS). 1 This study was performed in West Germany, Spain, Israel, Hungary, Sweden, Italy and Bulgaria, and estimated the excess risk for metamizole sodium-induced agranulocytosis to be between 0.06 and 1.1 per million users per week of treatment based on 79 million person-years of use. This was a factor of 10 less than the excess risk reported in the same study for other commonly used drugs such as the anti-thyroids, procainamide and sulphasalazine.
Meta-analysis of data from several epidemiological studies indicates that the absolute risk of mortality associated with metamizole sodium is 25 deaths per 100 million users, which is similar to paracetamol (20) and substantially lower than the risk associated with the frequently used nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin (185) and diclofenac (592). 11 Despite these data, metamizole sodium has continued to be the subject of pharmacopolitical debate with significant discrepancies in national policies regarding its use. 12 Some countries have withdrawn the product or restricted its use, while in many others, it continues to be used freely, sometimes being considered the analgesic of choice.
Given the ongoing debate about the safety of metamizole sodium and its extensive use in Poland, this study was undertaken to quantify the incidence of agranulocytosis associated with metamizole sodium and to compare the findings with reported incidences in other countries.
Patients and methods
Haematology clinics from Warsaw, Wroclaw, Lublin, Gdansk, -Lódź and Bialystok participated in this study. Clinics were chosen to provide a representative sample of in-patient, out-patient, adult and paediatric populations during the study period (1 January 1997 -31 December 2001), and were chosen without prior knowledge of their incidence of agranulocytosis. Each of the six centres received primary and secondary referrals for serious blood dyscrasias from the surrounding regions, a combined area covering approximately 40% of the population of Poland.
IDENTIFICATION OF CASES
The National Consultant in Haematology for Poland defined the diagnostic labels of agranulocytosis, granulocytopenia, aplastic anaemia or panmyelopthisis prior to the start of this study. A clinician from each site searched the patient records in each centre to identify all individuals with a relevant diagnosis during the study period.
A count of all identified cases was designated as the 'number registered'. As not all medical records were available, the count of those retrieved and reviewed was recorded as the 'number reviewed'. After exclusion of those who had received cytotoxic or other immunosuppressive therapy, those assessed to be valid cases by the centre's clinician were recorded as 'number data extracted'. For these cases, all available information was transcribed by a trained researcher and the centre clinician onto a data-abstraction form derived from an internationally acceptable set of data requirements for adverse-event reporting, 13 and included: (i) Data on the adverse event (onset, characteristics and time course); (ii) Results of blood and other diagnostic tests; (iii) Concomitant morbidity; (iv) Patient exposure to metamizole sodium, if any (dose/duration); (v) Information on other medication history (drug/dose/duration). In addition, normal laboratory ranges for blood counts were requested from each centre.
Cases with records of concurrent or recent use of metamizole sodium in relation to the diagnosis were recorded separately as 'number data extracted metamizole sodium'. The data on these cases were independently evaluated by one expert, the National Consultant in Haematology for Poland, for the association of the reaction/event to the use of metamizole sodium. Consideration was given to the onset of agranulocytosis in relation to the administration of metamizole sodium, alternative aetiological agents recorded on the form, recognition or comment by a physician that agranulocytosis was a possible adverse drug reaction, and the presence of confounding factors with respect to the patient's medical history or the use of other potentially implicated drugs.
COMPLETENESS OF DATA
An evaluation of the completeness of the abstracted data was made during the study by recording the number of retrieved medical records from which data on the five main areas identified above could be collected.
EXPOSURE TO METAMIZOLE SODIUM
As the defined daily dose (DDD) for metamizole sodium has not been established for Poland, a DDD of 3 g, derived from international data and adopted as the standard by the Polish Drug Institute, was used (Drug Institute, Warsaw, Poland, personal communication, February 2002). This represents the maximum recommended daily dose for all three formulations (tablets, ampoules and suppositories) of metamizole sodium available.
The unit sales for metamizole sodium provided to Polpharma S.A. (one of the largest manufacturers of pharmaceutical products in Poland; personal communication, March 2002) by IMS were interpreted from the pack and unit sales assumptions provided by the manufacturer (Table 1) .
Unit sales were used to derive the number of DDDs prescribed in any 1 year for each formulation and pack size of metamizole sodium. It has been assumed that all formulations, other than suppositories, are for adult use.
INTERNATIONAL COMPARISONS
A comprehensive search of the international literature was performed to determine what data existed on the incidence of agranulocytosis in association with the use of metamizole sodium.
Results

IDENTIFICATION OF CASES
During the study period, a total of 490 potential cases of agranulocytosis were identified from the records held at the six centres, and of these, 290 (59.2%) medical records were available for review. Data were extracted on 78 cases that had been assessed by the centre's physician as meeting the diagnostic criteria, of which six had a record of concurrent or recent metamizole-sodium use ( Table 2) .
Of the 78 cases reviewed, 11 (14.1%) were being treated for hyperthyroidism, nine (11.5%) had been exposed to chemical agents at work or in the environment, and six S Maj, Y Lis Metamizole sodium-induced agranulocytosis (7. 7%) had been exposed to metamizole sodium. The remaining patients had been exposed to a variety of other pharmaceutical products (many being given simultaneously), including anti-infectives, anti-hypertensives, neuroleptics, corticosteroids and other analgesics.
NUMBER OF CASES OF AGRANULOCYTOSIS ASSOCIATED WITH METAMIZOLE SODIUM
The formulation of metamizole sodium used in the six cases of agranulocytosis had not been recoded in the patients' medical records. As these were all adult cases presenting initially as out-patients, however, it was almost certain that they had all been exposed to the oral formulation.
The six cases identified included five females aged between 29 and 70 years (median age, 53 years) and one male aged 26 years. Four had been receiving therapy concurrent with other drugs (patient one, methotrexate; patient two, paracetamol; patient three, amoxicillin with clavulanic acid and rutoside with ascorbic acid; patient four, ticlopidine, captopril, dextromoramide, gliclazide, nabumetone, diclofenac and paracetamol). 
Assumption of unit sales
Tablets (500 mg) One pack is 10 tablets and one unit of sales represents 10 tablets Ampoules 2.5 g/(5 ml) One pack is five ampoules and one unit of sales represents five ampoules Suppositories 750 mg One pack is 10 suppositories and one unit of sales represents 10 suppositories Ampoules 1 g/2 ml One pack is five ampoules and one unit of sales represents five ampoules Ampoules 1 g/(50 × 2 ml) One pack is 50 ampoules and one unit of sales represents 50 ampoules
S Maj, Y Lis Metamizole sodium-induced agranulocytosis
In three of the six cases, the agranulocytosis was classified as serious. Two patients recovered, but the male patient who had been taking paracetamol concurrently died.
Causality to drug therapy was implied in the diagnosis made by the treating physician in three of the six cases. Two of these patients had received only metamizole sodium. The independent assessment of causality in relation to metamizole sodium categorized four cases as probably and two cases as possibly related to metamizole sodium administration.
None of the six cases identified had been reported to the Polish Drug Institute, which received only one report of agranulocytosis in association with the use of metamizole sodium in the 5 years covered by this study. This was in a 24-year-old female who had been using metamizole sodium suppositories (750 -1500 mg daily) over 4 years. In addition, this patient had been receiving ketonal (50 -100 mg orally), doxycycline (100 mg orally) and cyproterone acetate (one tablet orally) concurrently.
COMPLETENESS OF DATA ABSTRACTED
The comprehensiveness of the patient medical records was assessed as 'very good' in two centres, 'good' in two and 'adequate' in two.
Of the 78 cases from which data were abstracted, the medical records provided data that were approximately 70% complete. The information available met the minimum data requirements for the internationally accepted CIOMS II summary tabulation. The data most consistently absent were the dose and duration of drug therapy, and normal laboratory ranges for blood counts.
EXPOSURE TO METAMIZOLE SODIUM
The oral formulation of metamizole sodium is the most widely used in Poland, comprising approximately 72% of all DDDs sold during the 5-year study period (1997 -2001) . To calculate the incidence of agranulocytosis associated with metamizole sodium in this study, it has been assumed that all cases identified were exposed to the oral form only (Table 3 ).
INCIDENCE OF AGRANULOCYTOSIS ASSOCIATED WITH METAMIZOLE SODIUM USE
Because of the lack of data in the medical records, it was not possible for the expert to categorically determine the causation of agranulocytosis in each case. Therefore, all six cases identified have been assumed to be associated with the use of metamizole sodium.
To achieve a figure for the number of cases of agranulocytosis caused by metamizole sodium, the number of cases identified during this study (six) was first adjusted as only 60% of medical records of potential cases were reviewed (6/0.6 = 10). Secondly, the centres used in this study covered only 40% of the Polish population; therefore, a further adjustment was made to With the total number of person-days of exposure to oral metamizole sodium in Poland between 1997 and 2001 being 141 941 459, a crude estimate of the incidence of agranulocytosis associated with metamizole sodium is 0.2 cases per million person-days of use.
Discussion
Under-reporting of adverse events is a common feature in many countries. Even in Sweden, with its long history and culture of collecting spontaneous reports, only 25 -34% of druginduced cytopenias are reported. 14 In Poland, although a process for spontaneous reporting exists, the culture of reporting is not well established. Consequently, very little information is available on the safety of products when used in the general population.
Recognizing this situation, together with the extensive use of metamizole sodium in Poland and the various regulatory positions taken on this product by different countries, this study was undertaken to quantify the incidence of agranulocytosis associated with metamizole sodium and to compare the findings with those from other countries. Several specialist haematology centres representative of Poland were used, as most patients with blood dyscrasias would be referred to these units for treatment.
A crude estimate of the incidence of agranulocytosis associated with metamizole sodium in Poland calculated in this study found 0.2 cases per million person-days of use, which is at the low end but of the same order of magnitude as the overall incidence calculated from the IAAAS study 1 (0.3 -4.0 cases per million person-days of use). Adjustments for deficiencies in the data, such as the number of medical records retrieved (60%) and the lack of definite causality attribution, have been made in the calculation. However, some cases presenting to general hospitals rather than to specialist haematology units would have been missed. The IAAAS study also reported an incidence of one case per 20 000 users per year, demonstrating that the occurrence of agranulocytosis associated with metamizole sodium is a rare adverse event.
Only a few studies were identified in the literature that reported the risk of agranulocytosis associated with metamizole sodium. The majority of data were expressed as the number of cases per user population and were not therefore comparable with the data derived for Poland in this study. The information available from the published literature did, however, report a 10-fold difference in incidence (one case per 3000 14 -30 000 15 users per year).
The excess risk of agranulocytosis associated with metamizole sodium has been estimated to be between 0.06 and 1.1 per million users per week. This compares very favourably with the excess risk of agranulocytosis estimated for the NSAID indomethacin (0.2 per million users per week) and the excess risk for other commonly used drugs such as procainamide (10.0 per million users per week), anti-thyroid drugs (9.8 per million users per week) and penicillin (0.7 per million users per week). 16 In addition, the overall adverse reaction specific excess mortality (number per million short-term users) associated with metamizole sodium (0.076) was similar to that of paracetemol (0.033) and better than aspirin (1.5) and other NSAIDs (1.1 -14.9), which are dominated by the consequences of upper gastrointestinal perforations, ulcers or bleeds. 11 Similar findings are seen in another study in which the excess mortality associated with aspirin and diclofenac is higher (185 deaths/10 9 users and 592 deaths/10 9 users, respectively) than that associated with metamizole sodium (25 deaths/10 9 users). 17 The evidence available suggests that metamizole S Maj, Y Lis Metamizole sodium-induced agranulocytosis sodium has at least an equivalent, if not a better, risk-benefit profile than many other drugs that have not been the subject of such pharmacopolitical debate.
In the early days of use, all analgesic anti-pyretic drugs had been reported to be associated with agranulocytosis. 4 This was not surprising in view of the failure at that time to distinguish between the aetiology from significant drug exposure prior to onset of symptoms and the exposure connected with the treatment of symptoms of existing agranulocytosis such as fever and sore throat. Furthermore, most patients with agranulocytosis give histories of exposure to multiple drugs, including fixed combinations, thus making causal attribution difficult or impossible. 18 Judgements as to the offending drug tended to be made according to a prior suspicion rather than scientific criteria. 18 In addition, much of the information available at the time of regulatory decisions in the 1960s and 1970s was from reports of single cases, and it has been suggested that regulatory decisions were based on circumstantial rather than quantitative evidence. 12 By the 1970s, there were remarkable differences between countries in their attitudes to the use of this drug. In some countries, metamizole sodium was thought to cause such a high risk of agranulocytosis that its use was restricted or withdrawn, 19 while in many others it continued to be used freely, sometimes being considered the analgesic of choice.
Robust quantification of the incidence of metamizole sodium-induced agranulocytosis using well-designed epidemiological studies only became available in 1986 with the publication of the IAAAS study. This demonstrated that original estimates of incidence had been high. 19 Perhaps surprisingly, since the availability of the data from the IAAAS and other studies, discrepancies between national policies for metamizole sodium have continued. In countries such as Austria, Bulgaria, Croatia, Hungary, Romania and Slovakia, metamizole sodium is available as an over-the-counter product. In other countries, use of some formulations has been restricted or banned; however, most of these decisions appear not to have been based on quantification of the risk in the country concerned.
In Sweden, the decision to withdraw the product in 1974 was based on data from a study indicating that the incidence of argranulocytosis in association with metamizole sodium was 10 times higher (one in 3 000) 14 than that reported in the IAAAS study. The validity of the study in Sweden has subsequently been questioned. 2 Following re-introduction of the product in 1995, it was withdrawn again in 1999. However, the decision was based on data communicated only to Regulatory Authorities as a Rapid Alert, 20 which has not yet been published in the scientific literature.
It would seem that this study's attempt to quantify the risk of agranulocytosis associated with metamizole sodium use in Poland has produced similar results to those observed in most other countries where studies have been performed. It is also evident that there are adequate quantitative and comparative data available on metamizole sodium for Poland to make an informed and rational decision about its safety.
